Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis

Roberta Marolda, Chiara Ruocco, Chiara Cordiglieri, Chiara Toscani, Carlo Antozzi, Renato Mantegazza, Fulvio Baggi

Research output: Contribution to journalArticlepeer-review


Pixantrone was shown to reduce the severity of clinical manifestation in experimental myasthenia gravis. In the present work we further studied its therapeutic effect. Our results demonstrate that a single administration suppressed AChR-specific immune-responses in primed rats. However, clinical symptoms could be improved only by repeated drug administrations (q7dx6 protocol-8.12. mg/kg); this treatment allowed stable serum drug levels for at least 7. days, as assessed by a functional T-cell bioassay. Pixantrone exerted strong in vitro inhibitory effect only on proliferating T-cells without impairing dendritic cell differentiation and B-cell viability. Our data further demonstrate that Pixantrone is a promising immunosuppressant drug that should be investigated in myasthenia gravis.

Original languageEnglish
Pages (from-to)41-50
Number of pages10
JournalJournal of Neuroimmunology
Issue number1-2
Publication statusPublished - 2013


  • Acetylcholine receptor (AChR)
  • Experimental autoimmune myasthenia gravis (EAMG)
  • Immunomodulation
  • Pixantrone

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology


Dive into the research topics of 'Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis'. Together they form a unique fingerprint.

Cite this